002370 亚太药业
2025/09 - 九个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)9.2864.409-2.693-36.144-41.757
总资产报酬率 ROA (%)7.4322.419-0.804-8.466-12.799
投入资产回报率 ROIC (%)7.8912.597-0.876-9.195-14.103

边际利润分析
销售毛利率 (%)31.05631.16832.09335.77737.881
营业利润率 (%)42.6016.949-15.085-31.216-63.256
息税前利润/营业总收入 (%)54.75813.3605.198-25.200-56.270
净利润/营业总收入 (%)42.5728.451-2.824-35.532-72.439

收益指标分析
经营活动净收益/利润总额(%)-54.934-72.316551.94149.78676.828
价值变动净收益/利润总额(%)154.184160.806-32.98212.324-10.893
营业外收支净额/利润总额(%)-0.14318.356-448.72913.85111.073

偿债能力分析
流动比率 (X)10.2692.2945.9034.5194.650
速动比率 (X)9.6052.1255.3504.0904.366
资产负债率 (%)7.64230.64659.36280.23073.121
带息债务/全部投入资本 (%)1.21825.06752.49971.12264.228
股东权益/带息债务 (%)8,012.505294.93583.67730.46945.068
股东权益/负债合计 (%)1,208.514226.30668.45924.64136.760
利息保障倍数 (X)4.4822.7550.654-2.283-3.786

营运能力分析
应收账款周转天数 (天)117.58777.66472.13376.650107.158
存货周转天数 (天)105.410103.010116.376117.159115.651